The key members of the Vx Pharma team have exemplary credentials that are highly relevant to their respective business roles:

Dr Mark Fyvie (PhD, Cantab)Managing Director, CEO and Shareholder
Dr Fyvie is an entrepreneur focusing on South African technology ventures based on innovative business models. Prior to his appointment at Vx Pharma, he served as CEO of the Cape Biotech Trust, incubating investments in excess of $40m in new life-science ventures. As an internationally credentialed business strategy consultant, Mark has deployed in-depth understanding of novel innovation value with deep commercialisation expertise for pharmaceutical, biotech, clinical research, and e-finance organisations including FirstRand, Accenture, and Tartan Technology Limited. Mark has significant management experience at executive and board level. He holds a PhD from the University of Cambridge.
Dr Gil Mahlati (MB ChB, UKZN) (FCS, SA)Non-Executive Director (Chairman) and Shareholder
Dr Mahlati trained as a medical doctor before transitioning into a business career focusing on healthcare ventures with reach throughout the African continent. Previously, his core focus was the healthcare division of diversified holding group, Vuwa Investments, where he was an executive director and shareholder. Gil has held senior executive positions in many successful healthcare corporations, most notably as managing director of Enaleni Pharmaceuticals (now Cipla Medpro) and Amabhubesi Healthcare. Passionate about building world-class biopharmaceutical capacity in South Africa, Gil also holds non-executive directorships at a number of successful listed and private healthcare businesses. Currently, he is the chairman of the African Financial Group.
Dr Paul Abrahams (MB BCh, Wits) (MBA, Oxon)Medical Director and Shareholder
Dr. Abrahams practiced as an ER physician for several years. He was appointed as a research physician at a clinical trials unit based at the Chelsea and Westminster Hospital, London, in 1997 and subsequently read for an MBA at the University of Oxford before returning to South Africa where he joined a leading South African investment bank. In 2003 Paul left the banking world to focus on an entrepreneurial career where he has been involved in founding various healthcare start-up businesses as well as consulting to numerous established corporates in the sector. Paul continues to serve as a non-executive director to a number of businesses, including Vx Pharma, in the dynamic healthcare and technology sectors. His executive career is now focused on growing a dynamic new integrated healthcare services business in which he has a significant stake.